Aidol (Mefenamic Acid) is commonly used across therapeutic domains where short-term symptomatic assistance is needed to manage pain, inflammation, and fever. It helps address symptom clusters that may become intense or disruptive, and provides support that helps ease the overall symptom burden. It is generally considered relevant for easing mild to moderate pain and menstrual discomfort. It may assist with managing symptoms that can be intense or disruptive, and contributes to improved comfort during periods of heightened symptoms.

---

Key Therapeutic Applications

This medication is applied in situations involving certain distressing symptoms across several categories, including primary dysmenorrhea (painful periods), muscular aches, dental discomfort, and symptomatic management for conditions like rheumatoid arthritis or osteoarthritis. It is relevant when supportive symptom management is appropriate, applied during phases when symptoms become more noticeable.

“The medication supports patients during difficult episodes by easing distress and assists with maintaining functional stability.”

Quick Fact: Focus on Cyclical Symptom Management

Aidol is often used to address the pain associated with recurrent or episodic manifestations, and is considered relevant for easing discomfort linked to the menstrual cycle and related pelvic cramping.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Aidol?

Aidol (Mefenamic Acid) eligibility is strictly defined by official regulatory bodies to protect patient safety. The rules classify populations based on medical history, current health status, and age.

---

Absolute Prohibitions (Contraindications)

The medicine is contraindicated and must not be used by patients with a history of allergic reactions to mefenamic acid, aspirin, or other NSAIDs. Use is also prohibited for those with active gastrointestinal ulceration, a history of GI bleeding linked to NSAID use, severe heart failure, severe renal failure, or severe hepatic failure. Furthermore, Aidol is contraindicated during the third trimester of pregnancy and for the management of peri-operative pain in Coronary Artery Bypass Graft (CABG) surgery.

---

Age and Restricted Use

The medicine is generally approved for short-term use in adults and adolescents (typically 14 years and older). Use is not established in pediatric patients under 14 years. Caution is required for older adults (65 years and older) and those with mild to moderate kidney or liver impairment, who require medical monitoring. Use is not recommended for women who are breastfeeding or attempting to conceive.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Aidol (Mefenamic Acid) as described in government regulatory sources. All interactions are described at a high, regulatory-aligned descriptive level, focusing on classification and formal outcomes.

---

Interaction Classification and Constraints

Category	Regulatory Statement
Formal Contraindication	Contraindicated for treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
PK Interaction Basis	Metabolism is documented to occur via the CYP2C9 pathway.
Administration Timing	Co-administration with Mifepristone requires a separation interval; NSAIDs should not be taken for 8–12 days following its administration.

---

The most significant interaction structure is Pharmacodynamic Risk Amplification. Concurrent use with other Non-Aspirin Systemic NSAIDs is advised to be avoided due to additive gastrointestinal risk. Co-administration with Oral Anticoagulants (e.g., Warfarin), Corticosteroids, and SSRIs may enhance the risk of bleeding events. Antihypertensives (e.g., ACE inhibitors/ARBs) and Diuretics may have their efficacy decreased. Additionally, poor CYP2C9 metabolizers may exhibit abnormally high plasma levels. The risk for renal function impairment is heightened when combined with agents that rely on renal clearance, such as Lithium and Methotrexate. Concomitant use with alcohol is noted to increase the risk of gastrointestinal bleeding.

Molecular Targeting of Prostaglandin Synthesis

Aidol (Mefenamic Acid) works primarily by establishing a non-selective competitive inhibition of the Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. This mechanism acts as an early block within the Arachidonic Acid Cascade, drastically limiting the synthesis of lipid mediators, primarily PGE2 and PGF2alpha. The molecular consequence of this action is the restriction of signaling messengers involved in local inflammatory responses and hypothalamic temperature elevation.

---

Modulating Neural and Temperature Signaling Thresholds

The resulting reduction in PGE2 production leads to two simultaneous physiological consequences. Peripherally, it dampens the sensitization of nociceptors (pain-sensing neurons), raising the activation threshold required for signal transmission. Centrally, the mechanism restricts PGE2 signaling in the hypothalamus, facilitating the return of the central thermoregulatory set-point toward a normal physiological range. Furthermore, by inhibiting PGF2alpha, the drug modulates the hyperactivity of certain smooth muscle contractions. These targeted pathway interferences constitute the overall modulation of the affected physiological processes.

How to Use Aidol: Administration Guidelines

The usage of Aidol, containing Mefenamic Acid, is defined by specific guidelines. The medicine is for oral administration and is available in capsules (250 mg), tablets (500 mg), and oral suspension (50 mg/5 mL) forms.

Administration is generally structured for short-term, acute use and involves a higher initial quantity followed by a standard maintenance regimen. For conditions such as acute pain or primary dysmenorrhea, the initial dose is 500 mg, followed by a maintenance dose of 250 mg. This maintenance quantity is typically taken every six hours (q6h) as needed for symptoms, and for other indications, the regimen is 500 mg three times daily (t.i.d.).

Administration Conditions and Duration

Instruction	Guideline
Timing in Relation to Meals	Must be taken with food, milk, or a full glass of water (8–12 oz) to minimize gastrointestinal discomfort.
Acute Duration Limit	Treatment for acute pain should generally not exceed seven days (1 week).
Menstrual Duration Limit	Use for primary dysmenorrhea is limited, typically two to three days per menstrual cycle.

Population Use: Dosing for adolescents aged 14 years and older follows the adult regimen. In older adults, the general principle of using the lowest effective dose for the shortest duration applies. If a dose is missed, it must be skipped, and the regular schedule should be resumed; a dose must not be doubled.

This structured protocol governs the exact quantity, frequency, and duration of the medication's intake, defining its standardized approach to use.

Research Evidence / Overview of Studies for Aidol (Mefenamic Acid)

---

Evidence for Use in Primary Dysmenorrhea (Painful Periods)

Research has widely explored this medicine's potential role in the study of conditions characterized by fluctuating or episodic manifestations, such as painful menstrual cycles. These studies primarily involve high-quality, short-term Randomized Controlled Trials (RCTs) and Systematic Reviews.

The studies monitored patient-reported outcomes describing perceived discomfort and examined symptom patterns across the first few days of menstruation. The findings contribute to the broader evidence landscape by providing context on short-term symptom patterns related to this potential use. What remains uncertain is the effect of long-term or repeated use over many years, as follow-up durations were limited.

---

Evidence for Use in Mild to Moderate Acute Pain

The medicine was studied for its potential in the study of outcomes describing episodic or acute changes associated with physical discomfort. The evidence base includes single-dose, short-term RCTs for acute settings like dental and postoperative pain. Studies focused on episodes where symptoms become more noticeable, measuring outcomes such as the time to onset of measured response.

The data show patterns related to how symptom severity changed over short, defined time periods. These research findings are consistent with findings from multiple trials for this specific, short-duration evaluation in adult populations. The research explored short-term symptom changes, with trial durations typically restricted to seven days or less, meaning limited information exists for long-term outcomes.

---

Evidence for Symptomatic Management of Arthritis

Trials explored the medicine's potential role in the study of symptoms of inflammatory conditions like rheumatoid arthritis and osteoarthritis. Studies monitored changes in outcomes related to physical discomfort, such as pain and morning stiffness.

Trials reported documented measurements of changes in pain and stiffness within the study period. A key finding consistently confirmed that this medicine does not modify the underlying disease process or structural damage (like cartilage loss). Its research role is confined to evaluating symptomatic discomfort.

---

Evidence in Special Populations

Research has explored the potential role of this compound in various populations, including adolescents and children. The evaluation is typically restricted to adolescents 12 or 14 years and older, reflecting the age groups for which more established clinical trial data is available. Research is ongoing to better understand its effect and to address research gaps in younger children, where certainty remains low, particularly regarding long-term outcomes.

Key Studies & References

1. Clinical Guideline: Treatment of Osteoarthritis

Common questions about Aidol (FAQ)

Q: What is Aidol and what is it used for?

A: Aidol is a brand name for a medication containing the active ingredient paracetamol (also known as acetaminophen).

It belongs to a class of drugs called analgesics (pain relievers) and antipyretics (fever reducers).

Aidol is primarily used to temporarily relieve:

• Mild to moderate pain from conditions like headaches, muscle aches, backaches, minor arthritis pain, toothaches, and menstrual cramps.
• Fever associated with colds, flu, and other illnesses.

---

Q: How quickly does Aidol start to work?

A: Aidol generally starts to relieve pain or reduce fever within 30 to 60 minutes after taking an oral dose. The full effect may be noticeable soon after.

However, the exact time it takes to work can vary slightly depending on the specific formulation (e.g., tablet, liquid, extended-release) and individual factors.

---

Q: Can Aidol be taken with other pain relievers?

A: Aidol should not be taken with other products that also contain paracetamol (acetaminophen).

Paracetamol is a common ingredient in many over-the-counter and prescription combination medications for pain, fever, and cold/flu symptoms. Taking multiple products containing paracetamol can lead to an overdose and severe liver damage.

• Always check the active ingredients on all medications to ensure you are not accidentally taking more than one paracetamol-containing product.

• Consult a healthcare provider or pharmacist before combining Aidol with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen, or any other pain relievers, to ensure safety and prevent potential drug interactions.

---

Q: What is the maximum daily dose of Aidol?

A: The maximum recommended daily dose for most adults is typically 4,000 mg (4 grams) of paracetamol (the active ingredient in Aidol) in a 24-hour period.

• It is crucial not to exceed this limit as doing so significantly increases the risk of severe liver damage.

• Some healthcare providers may recommend a lower maximum daily dose, especially for individuals with existing liver problems, those who consume three or more alcoholic drinks per day, or those taking other medications. Always follow the specific instructions provided by your healthcare professional or the product label.

---

Q: What should I do if I accidentally take too much Aidol?

A: Seek immediate medical attention or contact a poison control center right away if you suspect an overdose, even if you do not feel sick.

Symptoms of an overdose may include nausea, vomiting, stomach pain, loss of appetite, sweating, and extreme tiredness, and may not appear until several hours after the overdose.

• Do not wait for symptoms to appear before getting help, as prompt treatment is essential to prevent permanent liver damage.

How to Store and Dispose of Aidol (Mefenamic Acid)

Storage and disposal protocols for Mefenamic Acid are defined by regulatory labeling to maintain product quality and public safety.

Storage Component	Official Requirement
Temperature	Store at Controlled Room Temperature, between 20 C and 25 C.
Protection	Protect from excess heat, light, and moisture. Do not store in the bathroom.
Container	Keep in the original container and keep the container tightly closed.
Child Safety	Mandatory instruction to keep the medicine out of the sight and reach of children.
Disposal	Utilize a drug take-back program or follow non-flushable household trash procedures; do not release into drains or waterways.

Adherence to these conditions ensures product stability. Disposal must follow local regulations for pharmaceutical waste.